What Are You Doing Now That Accula™ Is Going Away?
UPDATED: 8-15-2023
By Alison Adduono, Director of Marketing Communication
On April 11, 2023, Thermo Fisher Scientific announced it will discontinue the manufacturing and direct sales of the Thermo Fisher Accula™ line of products by April 26, 2023. After that date, the Accula™ products will ONLY be available for purchase through a select group of distributors while quantities last. The affected products are:
Accula™ Dock
Accula™ SARS-CoV-2 Test and Control Kit
Accula™ Flu A/Flu B Test and Control Kit
While this may not affect all Accula customers immediately, it is cause for concern given the potential for a surge in covid and flu cases in the coming weeks. Lack of available product will start to impact Accula customers’ daily operations. Customers looking for a reliable, highly precise, affordable and speedy molecular test for the point-of-care need look no further: Anavasi Diagnostics has just the solution for you. The AscencioDx system is the best Accula replacement. UPDATE: We are now hearing in the marketplace that Accula™ supplies are no longer available.
Earlier this year, Anavasi Diagnostics, based in Redmond, Washington, received an Emergency Use Authorization (EUA)* from the FDA for The AscencioDx® COVID-19 Test and The AscencioDx® Molecular Detector. Manufactured in the USA, Anavasi is committed to providing fast, accurate and widely available diagnostic capabilities to healthcare providers in Point of Care (POC) settings.
How Does AscencioDx® Measure Up to Accula™?
The AscencioDx measures up quite well to Accula when you compare its technology, benefits, and pricing. Both systems involve reverse transcription in-vitro amplification techniques used to produce thousands of copies of RNA and are Nucleic Acid Amplification Tests (NAATs). Where the Accula™ is an RT-PCR platform that performs dozens of heating and cooling cycles to help detect the presence of target RNA, the AscencioDx® is RT-LAMP and uses a single heating cycle and advanced biochemistry to complete similar detection of target RNA. RT-LAMP (reverse transcription loop-mediated isothermal amplification) is a much NEWER technology and leverages greater reliance on advanced probes and primers to work smarter and in many cases, faster.
The AscencioDx testing system uses RT-LAMP for the qualitative detection of RNA from the COVID-19 virus in samples that are heated and illuminated (via fluorescence signals) in a reaction tube placed within the detector. This patent-pending design has built-in target redundancy detecting three (3) distinct regions of the SARS-CoV-2 viral genome, making it very robust against mutation on any single n-gene location. In genomic sequence testing, The AscencioDx COVID-19 Test assay covers 99.99% of all current known variants and sub-variants such as Omicron and the latest XBB.1.16. For added assurance, the detector includes an internal control on every test sample to confirm test function.
AscencioDx Benefits:
Positive results in as little as 20 minutes, and most negative results in about 30 minutes
Less than 2 minutes of hands-on time required to set up the test
Uses lower nasal swab samples, making it easier to collect a sample specimen
Low-cost tests
Low-cost reusable molecular detector (good for at least 3,000 uses)
Compact sized detector: minimal footprint (can fit in the palm of your hand) using a 12-volt power adapter cable
Minimal biowaste, and significant biowaste disposal savings versus single-use platforms (e.g., Lucira Health).
Ideal Product Applications: healthcare professionals, physician office laboratories, urgent care providers, mobile testing, etc.
No Bluetooth or WiFi required to record or report results, improving cybersecurity and decreasing risk of HIPAA violations
Photo Credit: iStock by Getty Images
In addition to its affordability and ease of use, the AscencioDx system also includes a value-added test data management benefit at no extra charge. Anavasi Diagnostics has developed a unique detector portal to help you manage, store, and report patient test results. This system not only provides customizable report templates and one-step features, but it also reduces your LIMS and HER data entry by populating patient data with the scan of a driver’s license. The portal automatically disseminates results to the CDC and other required state and local health agencies through the CDC Report Stream, saving you a lot of time. Utilizing a scannable QR code to transmit test result, the detectors are secure – no Bluetooth or apps required.
For more information on The AscencioDx COVID-19 Test and The AscencioDx Molecular Detector please visit www.anavasidx.com or contact us at sales@anavasidx.com.
For a limited time, Anavasi Diagnostics will be offering an introductory package as well as a swap out program for existing Accula™ users. Contact us today for more details.
Innovation. Passion. Anavasi.
#accula #covid19testing #rtpcr #rtlamp #naat #moleculardiagnostics #rapiddiagnostics #POCT #pointofcare #rapidpcr #rapidtesting #covidtesting #uca #urgentcare
Note: The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector have not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
